<DOC>
	<DOCNO>NCT01777321</DOCNO>
	<brief_summary>The purpose study assess immunogenicity , safety , reactogenicity GSK Biologicals ' Herpes Zoster ( HZ ) vaccine ( GSK 1437173A ) administer subcutaneously ( SC ) compare intramuscularly ( IM ) people 50 year age old .</brief_summary>
	<brief_title>Safety Immunogenicity Study GSK Biologicals ' Herpes Zoster Subunit ( HZ/su ) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly Adults Aged ≥50 Years</brief_title>
	<detailed_description>There 2 treatment group study base upon mode vaccine administration . The humoral immunogenicity ( HI ) measure subject .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject , opinion investigator , comply requirement protocol . Subject , reside Japan , Japanese ethnic origin , define born Japan four ethnic Japanese grandparent able speak Japanese . Subject provide write informed consent . Subject , male female , 50 YOA old time first vaccination . Subject , female , nonchildbearing potential may enrol study . Subject , female , childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series ( i.e. , 2 month Month 2 ) . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Concurrently participate plan participation another clinical study , time study period , subject expose investigational noninvestigational product . Administration plan administration live vaccine within 30 day prior first study vaccination 30 day second study vaccination . Administration plan administration nonreplicating vaccine within 8 day prior within 14 day either dose study vaccine . Planned administration , study , HZ varicella vaccine ( include investigational nonregistered vaccine ) study vaccine . Administration immunoglobulins and/or blood product within three ( 3 ) month precede first dose study vaccine plan administration study period . Chronic administration ( defined &gt; 14 consecutive day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . For corticosteroid , prednisone dose &lt; 20 mg/day , equivalent , allow . Inhaled , topical , intraarticular corticosteroid allow . Administration plan administration longacting immunemodifying drug ( e.g. , infliximab ) within six month prior first vaccine dose duration study period . History HZ . Previous vaccination HZ varicella ( registered investigational product ) . History reaction hypersensitivity likely exacerbate component vaccine study material equipment . Significant underlying illness , opinion investigator , would expect prevent completion study . Any condition , opinion investigator , might interfere evaluation require study . Acute disease and/or fever time vaccination : Fever define temperature ≥37.5°C ( 99.5°F ) oral , axillary , tympanic route , ≥38.0°C/100.4°F rectal route . The preferred route record temperature study oral . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution ( childbearing potential ) Month 4 ( i.e. , 2 month second dose study vaccine ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Herpes Zoster</keyword>
	<keyword>Intramuscular</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Safety</keyword>
	<keyword>≥50 year age</keyword>
	<keyword>Adults</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Elderly</keyword>
</DOC>